Cargando…

Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience

BACKGROUND: The optimal treatment for recurrent high-grade gliomas (rHGGs) remains uncertain. This study aimed to investigate the efficacy and safety of hypofractionated stereotactic radiosurgery (HSRS) as a first-line salvage treatment for in-field recurrence of high-grade gliomas. METHODS: Between...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Yun, Xiong, Ji, Pan, Mingyuan, Shi, Wenyin, Li, Jing, Zhu, Huaguang, Gong, Xiu, Li, Chao, Mei, Guanghai, Liu, Xiaoxia, Pan, Li, Dai, Jiazhong, Wang, Yang, Wang, Enmin, Wang, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863415/
https://www.ncbi.nlm.nih.gov/pubmed/33546642
http://dx.doi.org/10.1186/s12885-021-07856-y
_version_ 1783647489525547008
author Guan, Yun
Xiong, Ji
Pan, Mingyuan
Shi, Wenyin
Li, Jing
Zhu, Huaguang
Gong, Xiu
Li, Chao
Mei, Guanghai
Liu, Xiaoxia
Pan, Li
Dai, Jiazhong
Wang, Yang
Wang, Enmin
Wang, Xin
author_facet Guan, Yun
Xiong, Ji
Pan, Mingyuan
Shi, Wenyin
Li, Jing
Zhu, Huaguang
Gong, Xiu
Li, Chao
Mei, Guanghai
Liu, Xiaoxia
Pan, Li
Dai, Jiazhong
Wang, Yang
Wang, Enmin
Wang, Xin
author_sort Guan, Yun
collection PubMed
description BACKGROUND: The optimal treatment for recurrent high-grade gliomas (rHGGs) remains uncertain. This study aimed to investigate the efficacy and safety of hypofractionated stereotactic radiosurgery (HSRS) as a first-line salvage treatment for in-field recurrence of high-grade gliomas. METHODS: Between January 2016 and October 2019, 70 patients with rHGG who underwent HSRS were retrospectively analysed. The primary endpoint was overall survival (OS), and secondary endpoints included both progression-free survival (PFS) and adverse events, which were assessed according to Common Toxicity Criteria Adverse Events (CTCAE) version 5. The prognostic value of key clinical features (age, performance status, planning target volume, dose, use of bevacizumab) was evaluated. RESULTS: A total of 70 patients were included in the study. Forty patients were male and 30 were female. Forty-nine had an initial diagnosis of glioblastoma (GBM), and the rest (21) were confirmed to be WHO grade 3 gliomas. The median planning target volume (PTV) was 16.68 cm(3) (0.81–121.96 cm(3)). The median prescribed dose was 24 Gy (12–30 Gy) in 4 fractions (2–6 fractions). The median baseline of Karnofsky Performance Status (KPS) was 70 (40–90). With a median follow-up of 12.1 months, the median overall survival after salvage treatment was 17.6 months (19.5 and 14.6 months for grade 3 and 4 gliomas, respectively; p = .039). No grade 3 or higher toxicities was recorded. Multivariate analysis showed that concurrent bevacizumab with radiosurgery and KPS > 70 were favourable prognostic factors for grade 4 patients with HGG. CONCLUSIONS: Salvage HSRS showed a favourable outcome and acceptable toxicity for rHGG. A prospective phase II study (NCT04197492) is ongoing to further investigate the value of hypofractionated stereotactic radiosurgery (HSRS) in rHGG. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-07856-y.
format Online
Article
Text
id pubmed-7863415
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78634152021-02-05 Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience Guan, Yun Xiong, Ji Pan, Mingyuan Shi, Wenyin Li, Jing Zhu, Huaguang Gong, Xiu Li, Chao Mei, Guanghai Liu, Xiaoxia Pan, Li Dai, Jiazhong Wang, Yang Wang, Enmin Wang, Xin BMC Cancer Research Article BACKGROUND: The optimal treatment for recurrent high-grade gliomas (rHGGs) remains uncertain. This study aimed to investigate the efficacy and safety of hypofractionated stereotactic radiosurgery (HSRS) as a first-line salvage treatment for in-field recurrence of high-grade gliomas. METHODS: Between January 2016 and October 2019, 70 patients with rHGG who underwent HSRS were retrospectively analysed. The primary endpoint was overall survival (OS), and secondary endpoints included both progression-free survival (PFS) and adverse events, which were assessed according to Common Toxicity Criteria Adverse Events (CTCAE) version 5. The prognostic value of key clinical features (age, performance status, planning target volume, dose, use of bevacizumab) was evaluated. RESULTS: A total of 70 patients were included in the study. Forty patients were male and 30 were female. Forty-nine had an initial diagnosis of glioblastoma (GBM), and the rest (21) were confirmed to be WHO grade 3 gliomas. The median planning target volume (PTV) was 16.68 cm(3) (0.81–121.96 cm(3)). The median prescribed dose was 24 Gy (12–30 Gy) in 4 fractions (2–6 fractions). The median baseline of Karnofsky Performance Status (KPS) was 70 (40–90). With a median follow-up of 12.1 months, the median overall survival after salvage treatment was 17.6 months (19.5 and 14.6 months for grade 3 and 4 gliomas, respectively; p = .039). No grade 3 or higher toxicities was recorded. Multivariate analysis showed that concurrent bevacizumab with radiosurgery and KPS > 70 were favourable prognostic factors for grade 4 patients with HGG. CONCLUSIONS: Salvage HSRS showed a favourable outcome and acceptable toxicity for rHGG. A prospective phase II study (NCT04197492) is ongoing to further investigate the value of hypofractionated stereotactic radiosurgery (HSRS) in rHGG. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-07856-y. BioMed Central 2021-02-05 /pmc/articles/PMC7863415/ /pubmed/33546642 http://dx.doi.org/10.1186/s12885-021-07856-y Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Guan, Yun
Xiong, Ji
Pan, Mingyuan
Shi, Wenyin
Li, Jing
Zhu, Huaguang
Gong, Xiu
Li, Chao
Mei, Guanghai
Liu, Xiaoxia
Pan, Li
Dai, Jiazhong
Wang, Yang
Wang, Enmin
Wang, Xin
Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience
title Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience
title_full Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience
title_fullStr Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience
title_full_unstemmed Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience
title_short Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience
title_sort safety and efficacy of hypofractionated stereotactic radiosurgery for high-grade gliomas at first recurrence: a single-center experience
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863415/
https://www.ncbi.nlm.nih.gov/pubmed/33546642
http://dx.doi.org/10.1186/s12885-021-07856-y
work_keys_str_mv AT guanyun safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience
AT xiongji safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience
AT panmingyuan safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience
AT shiwenyin safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience
AT lijing safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience
AT zhuhuaguang safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience
AT gongxiu safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience
AT lichao safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience
AT meiguanghai safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience
AT liuxiaoxia safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience
AT panli safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience
AT daijiazhong safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience
AT wangyang safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience
AT wangenmin safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience
AT wangxin safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience